Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...